Freedom Capital upgraded Biogen shares, and MarketBeat reported the consensus rating for the company.
7 reports, 2 independent
Updated Oct 13
Gone quiet
- Reports
- 7
- Developments
- 1
- Repetition
- 86%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Freedom Capital upgraded Biogen shares, and MarketBeat reported the consensus rating for the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Biogen
American multinational biotechnology company
-
Freedom Capital
company in the Czech Republic
-
MarketBeat
American personal finance blog
Related events
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- Jefferies predicts that Biogen will beat earnings expectations and see a share price move.
- Novavax stock is trading on the Nasdaq electronic stock exchange, with company news and ratings being aggregated by MarketBeat.
- Biogen and Marker Therapeutics are two healthcare companies that are currently competing for investment.
- reAlpha Tech Corp. stock traded on Nasdaq, with State Street, Geode, and Virtu increasing positions, and MarketBeat reporting ratings.